Inimmune gets grant for vaccine technology

By The Science Advisory Board staff writers

July 2, 2020 -- Montana-based Inimmune received a $2 million grant from the U.S. National Institute for Allergy and Infectious Diseases to develop novel adjuvant and delivery systems for vaccines.

The company will develop a stable and safe adjuvant delivery platform against a variety of infectious diseases, including COVID-19. Through the Small Business Innovation Research grant, Inimmune will develop a proprietary synthetic vaccine adjuvant -- components that stimulate and direct the immune system to enhance immunity to a vaccine. The two-year project will be led by Inimmune's Shannon Miller, PhD, and David Burkhart, PhD.

In June, Inimmune announced that they would be collaborating with the University of Montana's Center for Translational Medicine and Rocky Mountain Laboratories for the development of a nasal spray COVID-19 vaccine.


Copyright © 2020 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.